


# HbA1C/Glucose Point-of-Care Testing Clinical Tool



**Note:** Information provided in this resource pertain to most adults  $\geq 18$  years of age. For more information, including guidance specific to special populations (e.g., children, pregnancy), please refer to the [Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada](#).

**ABBREVIATIONS:**

**CANRISK:** Canadian Diabetes Risk Assessment Questionnaire; **FPG:** fasting plasma glucose; **HbA1C:** hemoglobin A1C/glycated hemoglobin; **OGTT:** oral glucose tolerance test; **OHIP:** Ontario Health Insurance Plan; **POCT:** point-of-care test; **PPG:** postprandial glucose; **T1DM:** Type 1 Diabetes Mellitus; **T2DM:** Type 2 Diabetes Mellitus

**DISCLAIMER:**

The Ontario Pharmacists Association (OPA) provides this material to pharmacy professionals for informational purposes only and is intended to assist pharmacy professionals with initiating discussions with patients about point-of-care testing but does not replace professional judgment and responsibilities. It is provided without warranty of any kind and OPA assumes no responsibility for any errors, omissions or inaccuracies therein. The decision for use and application of this document is the responsibility of the user. OPA assumes no liability for such use and application or any resulting outcomes. It is the responsibility of the pharmacy professional to use professional judgment in evaluating this material in light of any relevant clinical or situational data. It is intended to supplement materials provided by regulatory authorities, and should there be any discrepancies, municipal, provincial, and federal laws, policies and guidelines shall prevail. This information is up to date as at the date of publication. Pharmacy professionals are encouraged to confirm information with additional resources.

**REFERENCES:**

- Diabetes Canada Clinical Practice Guidelines Expert Committee, Ekeo J M, Goldenberg, R. & Katz, P. (2018). Screening for Diabetes in Adults. *Canadian journal of diabetes*, 42 Suppl 1 S16-S19. <https://doi.org/10.1016/j.jcjd.2017.10.004>
- Diabetes Canada Clinical Practice Guidelines Expert Working Group, Cheng, A, Feig, D. S., Ho, J, Siemens, R. & Diabetes Canada Clinical Practice Guidelines Steering Committee (2021). Blood Glucose Monitoring in Adults and Children with Diabetes: Update 2021. *Canadian journal of diabetes*, 45(7), 580-587. <https://doi.org/10.1016/j.jcjd.2021.07.003>
- Diabetes Canada (2018, May 18). *Self-Monitoring of Blood Glucose (SMBG) Recommendation Tool for Health-care Providers*. Accessed June 10, 2022. <https://guidelines.diabetes.ca/docs/resources/self-monitoring-blood-glucose-recommendation-tool.pdf>
- Diabetes Canada Clinical Practice Guidelines Expert Committee, Beard, L. D., Siemens, R. & Woo, V. (2018). Monitoring Glycemic Control. *Canadian journal of diabetes*, 42 Suppl 1 S47-S53. <https://doi.org/10.1016/j.jcjd.2017.10.007>
- Mansell, K & Arnason, T. Diabetes Mellitus. (2021). *Therapeutic Choices*. Canadian Pharmacists Association. Accessed June 9, 2022. <http://www.myrx.ca>
- Ministry of Health, Ontario Health Insurance Plan: Laboratories and Genetics Branch. (2020, July 1). *Schedule of Benefits for Laboratory Services*. Government of Ontario. Accessed March 25, 2022. [https://www.health.gov.on.ca/en/pro/programs/ohip/sob/lab/lab\\_mn2020.pdf](https://www.health.gov.on.ca/en/pro/programs/ohip/sob/lab/lab_mn2020.pdf)
- Florkowski, C., Donovan-Wauchope, A., Gimenez, N., Rodriguez-Capote, K., Wils, J. & Zemlin, A. (2017). Point-of-care testing (POCT) and evidence-based laboratory medicine (EBLM) - does it leverage any advantage in clinical decision making?. *Critical reviews in clinical laboratory sciences*, 54(7-8), 471-494. <https://doi.org/10.1080/10408363.2017.1399336>
- Nichols, J. H. (2020). Chapter 19 - Point-of-care testing. In W. Clarke & M. A. Marzinko (Eds.), *Contemporary Practice in Clinical Chemistry (Fourth Edition)* (pp. 323-336). Academic Press. <https://doi.org/10.1016/B978-0-12-815499-1.00019-3>
- Government of Canada. (2021, March 19). *Safe Medical Devices in Canada*. Accessed May 11, 2022. <https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/activities/fact-sheets/safe-medical-devices-fact-sheet.html>
- Health Quality Ontario (2014). Point-of-Care Hemoglobin A1c Testing: An Evidence-Based Analysis. *Ontario health technology assessment services*, 14(8), 1-30.
- Rebel, A., Rice, M. A., & Fahy, B. G. (2012). Accuracy of point-of-care glucose measurements. *Journal of diabetes science and technology*, 6(2), 396-411. <https://doi.org/10.1177/193229681200600228>
- Diabetes Canada Clinical Practice Guidelines Expert Committee, Imran, S. A., Agarwal, G., Bajaj, H. S., & Ross, S. (2016). Targets for Glycemic Control. *Canadian journal of diabetes*, 42 Suppl 1 S42-S46. <https://doi.org/10.1016/j.jcjd.2017.10.030>